Share with wechat scanning QR code < / P > < p > to friends and circles of friends < / P > < p > < / P > < p > on March 18, nuohui health today released its annual performance report for the year ended December 31, 2021. According to the financial report, Novell health achieved a total operating revenue of 210 million yuan in 2021, an increase of 201.5% year-on-year over 2020; The gross profit was 150 million yuan, a year-on-year increase of 315.2% over 2020; The gross profit margin rose to 72.7% from 52.8% in 2020. The total revenue of the company in 2020 is about 71 million yuan and the gross profit is about 37 million yuan. By the end of 2021, the total capital of the company, including time deposits, cash and cash equivalents, was 1.89 billion yuan < p > nuohui Health said that the company's youyouguan has been approved for registration of class III medical devices by the State Drug Administration, becoming the first Helicobacter pylori detection product 1 suitable for "consumer self-test" in China. It has realized the integrated patent design of "pregnancy test stick" for sampling and detection for the first time, and has been verified by the registered clinical trial supervised by the State Drug Administration to meet the accuracy, safety and convenience requirements of "consumer self-test" < p > "in 2021, Novelli health proved the scale and potential of China's cancer early screening market with its performance, and took the lead in running out of the two brands and products with a revenue of 100 million yuan, Chang Weiqing and puff tube. The substantial increase in the company's revenue and gross profit margin in 2021 was due to the strong growth of sales and the improvement of the contribution ratio of high-quality channels. Youyouguan, which was listed strongly in early 2022, also provided a new driving force for the company's growth." Zhu Yeqing, CEO of nuohui health, said, "Over the past few years, the firm investment in market education and academic promotion of the company has established nuohui health's leading position in the cancer early screening industry and laid a solid foundation for the company to maintain strong growth. At the same time, in 2021, we focused on expanding the company's multi group technology platform and industry breakthrough innovation pipeline R & D. the R & D investment has increased nearly three times compared with 2020, and the number of patents and patent applications owned by the company has also increased from 71 last year Increased to 169 items, laying a solid foundation for the company's long-term development. Nuohui health will continue to conduct product R & D, clinical and registration in a serious medical mode, and serve users in a consumer medical mode. Meanwhile, the company's goal of achieving breakeven in 2024 remains unchanged. " < p > the financial report shows that Chang Weiqing achieved a revenue of 97.2 million yuan in 2021, and the annual delivery volume exceeded 660000 boxes, with a year-on-year increase of 168% over 2020; The home self-test fecal occult blood (FIT) testing product puff tube achieved an income of nearly 120 million yuan in 2021, and the annual delivery volume exceeded 5.8 million people, with a year-on-year increase of 104% over 2020; Chang Weiqing's gross profit margin increased from 66.9% in the same period of 2020 to 76.0% in 2021, and poopoo Guan's gross profit margin increased from 45.8% in the same period of 2020 to 71.5% in 2021